IO Biotech Inc
IOBT
View Detailed Chart
0.890USD
+0.051+6.09%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
58.62MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.09%
5 Days
+1.74%
1 Month
+84.61%
6 Months
-21.95%
Year to Date
-3.28%
1 Year
-22.63%
View Detailed Chart
TradingKey Stock Score of IO Biotech Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
IO Biotech Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
2.463
Target Price
+193.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
IO Biotech Inc Highlights
StrengthsRisks
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.58, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.06M shares, decreasing 24.13% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 139.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 13.93.
IO Biotech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
IO Biotech Inc Info
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Ticker SymbolIOBT
CompanyIO Biotech Inc
CEODr. Mai-Britt Zocca, Ph.D.
Websitehttps://www.iobiotech.com/
Related Instruments
+2.09%
-0.46%
+0.41%
-1.07%
+0.39%
+0.63%
+7.81%
+0.44%
-0.34%
+1.28%
-0.22%
-1.11%
+0.31%
+1.93%
-0.28%
-0.11%
0.00%
+2.58%
+2.62%
-3.19%Popular Symbols
